Ophthalmic Patents (Class 514/912)
-
Patent number: 8207215Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: October 17, 2007Date of Patent: June 26, 2012Assignee: Allergan, Inc.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
-
Patent number: 8207226Abstract: Methods of treating symptoms of dry eye by administering a fatty acid amide or inhibitors of fatty acid amide hydrolase (FAAH) are disclosed. Methods of preventing or alleviating ocular pain by administering a fatty acid amide or FAAH inhibitors are also disclosed.Type: GrantFiled: June 2, 2009Date of Patent: June 26, 2012Assignee: Alcon Research, Ltd.Inventors: Martha E. Gadd, Karen C. David
-
Patent number: 8183291Abstract: A clear ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V), 0.003 to 0.01% (W/V) benzalkonium chloride and at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic. A method of preventing white turbidity in an ophthalmic solution containing latanoprost having a concentration of 0.005% (W/V) and 0.003 to 0.01% (W/V) benzalkonium chloride, the method involving adding to the solution at least one agent selected from the group consisting of glycerin, polyethylene glycol, propylene glycol and trehalose, wherein the agent is in a concentration to make the solution isotonic.Type: GrantFiled: August 26, 2010Date of Patent: May 22, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Asada, Akio Kimura
-
Patent number: 8168655Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.Type: GrantFiled: May 17, 2006Date of Patent: May 1, 2012Assignee: SARcode Bioscience Inc.Inventors: Thomas Gadek, John Burnier
-
Patent number: 8163726Abstract: The present invention relates to compositions and methods for inhibiting unwanted angiogenesis, particularly those of ocular tissues. The treatment, inhibition, and/or prevention of choroidal neovasculature (CNV) is provided, along with an animal model for CNV and imaging techniques that permit the screening of potential agents as anti-angiogenesis and anti-CNV agents.Type: GrantFiled: September 18, 2003Date of Patent: April 24, 2012Assignee: University of PennsylvaniaInventors: Rong Wen, Zhijun Luo, Alan M. Laties
-
Patent number: 8143312Abstract: An object of the present invention is to provide better formulations of a latanoprost ophthalmic solution. The present invention provides a clear ophthalmic solution comprising latanoprost as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least one means selected from the following 1) to 3); 1) adding a surfactant, 2) using benzalkonium chloride represented by the formula of [C6H5CH2N(CH3)2R]Cl (wherein R is alkyl having 12 carbon atoms) as the preservative and 3) adding a nonionic tonicity agent as a tonicity agent.Type: GrantFiled: September 8, 2003Date of Patent: March 27, 2012Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Asada, Akio Kimura
-
Patent number: 8138156Abstract: Ophthalmic composition comprising one or more polyglycines selected from the group consisting of diglycine, triglycine, tetraglycine and pentaglycine, or the salts of each thereof and one or more boron buffering compounds. The ophthalmic composition will have an osmolality of from 200 mOsmol/kg to 420 mOsmol/kg.Type: GrantFiled: October 17, 2007Date of Patent: March 20, 2012Assignee: Bausch & Lomb IncorporatedInventors: Susan E. Burke, Erning Xia, Catherine Scheuer, Srini Venkastesh
-
Patent number: 8119112Abstract: Ophthalmic compositions that comprise 0.1 ppm to 10 ppm of a cationic antimicrobial component selected from the group consisting of biguanides, polymeric biguanides, quaternium ammonium compounds and any one mixture thereof; 0.005 wt. % to 0.15 wt. % of hyaluronic acid; and 0.01 wt. % to 1.0 wt. % of an amphoteric surfactant of general formula I wherein R1 is R or —(CH2)n—NHC(O)R, wherein R is a C8-C16alkyl optionally substituted with hydroxyl and n is 2, 3 or 4; R2 and R3 are each independently selected from methyl, ethyl, propyl or iso-propyl; and R4 is a C2-C8alkylene optionally substituted with hydroxyl. The invention is also direct to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.Type: GrantFiled: September 3, 2008Date of Patent: February 21, 2012Assignee: Bausch & Lomb IncorporatedInventors: Erning Xia, Susan E. Burke, Srini Venkatesh, Vicki Barniak
-
Patent number: 8106038Abstract: This invention relates generally to the field of pharmacotherapeutics and the use of photodynamic therapy (“PDT”). In particular, the invention provides a method for reducing or preventing the effects of inflammation arising from normal dose photodynamic therapy (PDT), which method comprises exposing a target tissue in a subject that has been treated with normal dose PDT treatment to low dose light having a wavelength absorbed by a photosensitizing agent used in said normal dose PDT treatment for a time sufficient to reduce or prevent the effects of inflammation arising from said normal dose PDT treatment. The method is particularly useful in reducing or preventing the effects of inflammation arising from normal dose PDT treatment of ocular tissues.Type: GrantFiled: February 15, 2002Date of Patent: January 31, 2012Assignee: QLT Inc.Inventors: Philippe Maria Clotaire Margaron, Anna M. Richter, Julia G. Levy
-
Patent number: 8101582Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.Type: GrantFiled: July 22, 2010Date of Patent: January 24, 2012Assignee: Alcon Research, Ltd.Inventor: Bhagwati P. Kabra
-
Patent number: 8101635Abstract: Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.Type: GrantFiled: July 6, 2004Date of Patent: January 24, 2012Assignee: Allergan, Inc.Inventor: Evan B. Dreyer
-
Patent number: 8097600Abstract: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5?-triphosphate (UTP), dinucleotides, cytidine 5?-triphosphate (CTP), adenosine 5?-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: GrantFiled: June 28, 2010Date of Patent: January 17, 2012Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Karla M. Jacobus, William Pendergast, Janet L. Rideout
-
Patent number: 8097646Abstract: There is provided an ophthalmic pharmaceutical preparation comprising menthyl ester of indomethacin as an active ingredient. Also provided are different possible formulations of the ophthalmic preparation, and different methods of treating ophthalmic irritation using the ophthalmic preparation.Type: GrantFiled: November 7, 2006Date of Patent: January 17, 2012Assignee: AlphaRx, Inc.Inventors: Joseph Schwarz, Michael Weisspapir
-
Patent number: 8088773Abstract: The present invention relates in general to therapeutic compositions and methods of use. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In some embodiments, the invention relates to compositions and methods of improving vision.Type: GrantFiled: May 3, 2006Date of Patent: January 3, 2012Assignee: The Texas A&M University SystemInventor: George C. Chiou
-
Patent number: 8067406Abstract: An alkyl ether derivative represented by the following general formula [1] or its salt: wherein R1 and R2 represent each a substituent such as hydrogen, halogeno or alkyl; R3 represents alkylamino, amino or hydroxyl; the ring A represents a 5- or 6-membered aromatic heterocycle or a benzene ring; m and n are each an integer of from 1 to 6; and p is an integer of from 1 to 3; shows an effect of protecting retinal nerve cells and, therefore, is useful as a preventive and/or a remedy for retinal nerve diseases such as glaucoma, diabetic retinopathy, retinal artery obstruction, retinal venous obstruction, macular degeneration and retinopathy of prematurity.Type: GrantFiled: January 19, 2011Date of Patent: November 29, 2011Assignee: Toyama Chemical Co., Ltd.Inventors: Tatsuo Kimura, Noboru Iwakami, Akihito Saitoh
-
Patent number: 8067405Abstract: The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.Type: GrantFiled: March 24, 2010Date of Patent: November 29, 2011Assignee: Novartis AGInventors: Peter G. Klimko, Robert J. Collier, Jr., Mark R. Hellberg
-
Patent number: 8063054Abstract: A composition including diazoxide (7-chloro-3-methyl-2H-1,2,4-benzothiadiazine-1,1-dioxide) for the treatment and/or prevention of retinal ischemia and of diseases associated with retinal ischemia. The composition can also contain riluzole, a derivative active in neuroprotection of the latter, or a pharmaceutically acceptable salt of the latter.Type: GrantFiled: September 7, 2005Date of Patent: November 22, 2011Assignees: Centre National de la Recherche Scientifique-CNRS, Universite de Nice-Sophia AntipolisInventors: Michel Lazdunski, Mohamed Ettaiche
-
Patent number: 8057808Abstract: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.Type: GrantFiled: April 21, 2010Date of Patent: November 15, 2011Assignee: Allergen, Inc.Inventor: Alan H. Ackerman
-
Patent number: 8053407Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.Type: GrantFiled: October 31, 2007Date of Patent: November 8, 2011Assignee: Sygnis Bioscience GmbH & Co. KGInventors: Wolf-Ruediger Schaebitz, Armin Schneider, Carola Krueger, Clemens Sommer, Stefan Schwab, Rainer Kollmar, Martin Maurer, Daniela Weber, Nikolaus Gassler
-
Patent number: 8043607Abstract: Dihydroxybenzotriazole UV absorbing compounds that are particularly useful in ophthalmic devices are disclosed.Type: GrantFiled: July 10, 2009Date of Patent: October 25, 2011Assignee: Novartis AGInventor: David L. Jinkerson
-
Patent number: 8030349Abstract: The present invention provides a method for preventing the degradation of a thermally unstable medicament in an eye drop containing the medicament thereby to stabilize the eye drop. By adding an organic amine to an eye drop containing a thermally unstable medicament, the degradation of the medicament in the eye drop can be effectively prevented, and therefore the eye drop can be stably stored.Type: GrantFiled: August 2, 2006Date of Patent: October 4, 2011Assignee: Santen Pharmaceutical Co., Ltd.Inventors: Hiroyuki Asada, Akio Kimura
-
Patent number: 8025651Abstract: A urinary anti-backflow device is provided which prevents urine from flowing back into the patient's bladder from a urine collection bag. The device comprises a flow tube having an upstream section connectable to an external urinary device secured to a patient and a downstream section connectable to a urine collection bag, a rod within the flow tube, and a stopper which moves along the rod between the downstream and upstream ends of the flow tube. When the upstream section of the flow tube is elevated relative to the downstream section, urine from the patient is free to flow through the flow tube. When the downstream section of the flow tube is elevated relative to the upstream section, urine forces the stopper against the upstream section to prevent backflow.Type: GrantFiled: March 17, 2009Date of Patent: September 27, 2011Inventor: Carl Hart
-
Patent number: 8008338Abstract: Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.Type: GrantFiled: May 28, 2004Date of Patent: August 30, 2011Assignee: Allergan, Inc.Inventors: Christopher A. Muller, Janet K. Cheetham, Teresa H. Kuan, David F. Power
-
Patent number: 8003635Abstract: The use of SOD mimics particularly pentaazacycle Mn(II) complex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.Type: GrantFiled: April 23, 2010Date of Patent: August 23, 2011Assignee: Novartis AGInventors: Peter G. Klimko, Robert J. Collier, Jr., Mark R. Hellberg
-
Patent number: 7998942Abstract: The present invention provides an ophthalmic solution containing xanthan gum and terpenoid, which shows a suppressed decrease in the terpenoid content, by the addition of xanthan gum to an ophthalmic solution containing terpenoid.Type: GrantFiled: July 11, 2006Date of Patent: August 16, 2011Assignee: Senju Pharamaceutical Co., Ltd.Inventors: Fukiko Nemoto, Koji Doi, Hiroshii Aki
-
Patent number: 7977385Abstract: Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g.Type: GrantFiled: March 14, 2003Date of Patent: July 12, 2011Assignee: Numoda Biotechnologies, Inc.Inventors: Vicken H. Karageozian, David Castillejos, John Park, Gabriel Arthuro Carpio Aragon, Jose Luis Gutierres Floress
-
Patent number: 7947729Abstract: A compound having preferential localization in tumor tissue relative to normal tissue, a preferential electromagnetic absorption at a wavelength between about 660 and 900 nm, and a fluorescence at a wavelength shifted from the preferential absorption by at least +30 nm and preferably at least +50 nm. The compound further preferably destroys tumor tissue in which it is absorbed when exposed to light at its preferential absorption wavelength. In a preferred embodiment of the invention, the compound is a conjugate of a tumor avid tetrapyrrole compound with a fluorescent dye, and more preferably the fluorescent dye is an indocyanine dye such as indocyanine green. The tumor avid tetrapyrrole compound is preferably a porphyrin derivative selected from the group consisting of chlorins, bacteriochlorins, purpurins and derivatives thereof.Type: GrantFiled: July 13, 2005Date of Patent: May 24, 2011Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, Yihui Chen, William Potter, Allan Oseroff
-
Patent number: 7923469Abstract: Compositions for caring for contact lenses and eyes include a liquid aqueous medium and a vitamin derivative component present in an amount effective as a surfactant in the composition. The compositions can be used to clean, soak, re-wet and, with the inclusion of a disinfectant, disinfect contact lenses. In addition, the compositions are effective as artificial tears and eye wash solutions. Methods for contact lens care and eye care are also disclosed.Type: GrantFiled: April 24, 2002Date of Patent: April 12, 2011Assignee: Allergen, Inc.Inventors: Stanley Huth, Richard Chadwick, Gerry Franco
-
Patent number: 7919094Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: GrantFiled: December 22, 2006Date of Patent: April 5, 2011Assignees: Omeros Corporation, University of LeicesterInventors: Hans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E Tedford, James B Parent, Teizo Fujita
-
Patent number: 7915312Abstract: The present invention is directed to a physiological method for improving vision in a human patient. This method involves topical application to the eye, an amount of acetylcholine esterase inhibitor containing composition so that it is sufficient to provide a therapeutic benefit to improve the visual acuity in the human patient. The composition is administered topically and at bedtime after an eye straining work for about 20 minutes. The method disclosed herein is used for treatment and prevention of congenital and acquired color vision blindness, treatment of ocular hypertension and glaucoma, prevention of the progression of myopia, treatment of strabismus or squint, potentiation of best visual acuity, neuro-protection, treatment of aberrations secondary to pupil dilation.Type: GrantFiled: March 17, 2003Date of Patent: March 29, 2011Inventor: Gerard M. Nolan
-
Patent number: 7906498Abstract: Topical application of cholesterol has been found to be effective in preventing, treating or ameliorating the damage to the cornea caused by Streptococcus pneumoniae. Topical administration of cholesterol caused a significant decrease in the inflammation of the eye. In addition, cholesterol was surprisingly found to be a bactericide to Streptococcus pneumoniae outside the cornea. The effect of cholesterol can be enhanced by further administering a steroid or an antibiotic to the cornea.Type: GrantFiled: April 6, 2005Date of Patent: March 15, 2011Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical CollegeInventors: Mary E. Marquart, Richard J. O'Callaghan
-
Patent number: 7897642Abstract: Compositions and methods to inhibit dry eye as well as other conditions are provided.Type: GrantFiled: June 18, 2003Date of Patent: March 1, 2011Inventor: Irvine Dubow
-
Patent number: 7842722Abstract: The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision. The dietary supplements of the invention contain cobeadlets comprising vitamin E and carotenoids in the form of Vitamin A, lutein and/or zeaxanthing. The dietary supplements of the invention further contain Vitamin C, copper and zinc and may also contain such ingredients as rosemary, DHA, other vitamins and minerals.Type: GrantFiled: December 14, 2004Date of Patent: November 30, 2010Assignee: Alcon, Inc.Inventor: John C. Lang
-
Patent number: 7842367Abstract: Opthalmic devices, particularity intraocular lenses (IOL), with improved contrast sensitivity and methods of making same. In one aspect, blue light blocking chromophores (BLBC) are diffused into, e.g. an IOL lens body to create a BLBC gradient in the lens. Orange dyes are preferred BLBCs.Type: GrantFiled: February 8, 2006Date of Patent: November 30, 2010Assignee: Key Medical Technologies, Inc.Inventor: Khalid Mentak
-
Patent number: 7825102Abstract: The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A3 adenosine receptor (A3AR) agonist, the amount being effective to ameliorate symptoms of dry eye in the individual. In accordance with one embodiment, the dry eye condition is manifested by one or more ophthalmologic clinical symptoms selected from foreign body sensation, burning, itching, irritation, redness, eye pain, blurred vision, degraded vision and excessive tearing. A preferred A3RAg in accordance with the invention is N6-(3-iodobenzyl)-adenosine-5?-N-methyluronamide (IB-MECA).Type: GrantFiled: November 28, 2006Date of Patent: November 2, 2010Assignee: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Tatiana Reitblat, Ilan Cohn
-
Patent number: 7820639Abstract: Ophthalmic compositions are provided that include a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided.Type: GrantFiled: September 30, 2005Date of Patent: October 26, 2010Inventor: Richard L. Lindstrom
-
Patent number: 7795316Abstract: Ophthalmic pharmaceutical compositions containing tobramycin, dexamethasone and deacetylated xanthan gum are described. The compositions provide longer ocular retention for enhanced ocular bioavailability of tobramycin and dexamethasone. In a preferred embodiment, the compositions also provide for improved suspension of dexamethasone. The concentration of ionizable species in the compositions is controlled so as to prevent precipitation of the xanthan gum as a result of ionic interactions between tobramycin and xanthan gum, while allowing for a restoration of viscosity upon topical application of the compositions to the eye. The use of deacetylated xanthan gum is disclosed, so as to avoid formulation instability caused by pH drift during storage.Type: GrantFiled: December 19, 2007Date of Patent: September 14, 2010Assignee: Alcon Research, Ltd.Inventor: Bhagwati P. Kabra
-
Patent number: 7776907Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.Type: GrantFiled: October 30, 2003Date of Patent: August 17, 2010Assignee: Celgene CorporationInventor: Jerome B. Zeldis
-
Patent number: 7763619Abstract: Compositions and methods for treating disorders of the outer retina with compounds with 5-HT1A agonist activity are disclosed.Type: GrantFiled: July 22, 2005Date of Patent: July 27, 2010Assignee: Alcon, Inc.Inventors: Robert J. Collier, Jr., Michael A. Kapin, Mark R. Hellberg, Thomas R. Dean
-
Patent number: 7759333Abstract: The use of SOD mimics particularly pentaazacycle Mn(II) complex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.Type: GrantFiled: December 6, 2002Date of Patent: July 20, 2010Assignee: Alcon, Inc.Inventors: Peter G. Klimko, Robert J. Collier, Jr., Mark R. Hellberg
-
Patent number: 7759322Abstract: A method and preparation for the stimulation of tear secretion in a subject in need of such treatment is disclosed. The method comprises administering to the ocular surfaces of the subject a purinergic receptor agonist such as uridine 5?-triphosphate (UTP), dinucleotides, cytidine 5?-triphosphate (CTP), adenosine 5?-triphosphate (ATP), or their therapeutically useful analogs and derivatives, in an amount effective to stimulate tear fluid secretion and enhance drainage of the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation or suppository form.Type: GrantFiled: June 20, 2007Date of Patent: July 20, 2010Assignee: Inspire Pharmaceuticals, Inc.Inventors: Benjamin R. Yerxa, Karla M. Jacobus, William Pendergast, Janet L. Rideout
-
Patent number: 7754765Abstract: In various aspects, the invention provides methods for treating ocular inflammation using copper chelating compounds, such as compounds other than D-penicillamine. In some embodiments, such compounds may be polyamines, such as triethylenetetramine or tetraethylenepentamine. For example, the present invention provides methods for treating inflammation secondary to ocular laser therapy.Type: GrantFiled: May 30, 2003Date of Patent: July 13, 2010Assignee: Radical Vision Therapeutics IncInventors: Xuefeng Wang, Jing Z. Cui, Joanne A. Matsubara
-
Patent number: 7754706Abstract: The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.Type: GrantFiled: December 5, 2003Date of Patent: July 13, 2010Assignee: Alcon, Inc.Inventors: Peter G. Klimko, Robert J. Collier, Jr., Mark R. Hellberg
-
Patent number: 7745461Abstract: The topical use of EgLN-3 inhibitors is disclosed for the treatment of dry eye.Type: GrantFiled: February 26, 2007Date of Patent: June 29, 2010Assignee: Alcon Research, Ltd.Inventor: Peter G. Klimko
-
Patent number: 7732425Abstract: An ophthalmic pharmaceutical composition comprising trehalose as an effective ingredient and a pharmaceutically-acceptable carrier. The pharmaceutical composition is a safe, long-term continuously-administrable, therapeutic and/or prophylactic agent for the ophthalmologic clinical symptoms and signs in Sjögren syndrome.Type: GrantFiled: March 24, 2003Date of Patent: June 8, 2010Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Toshihiko Matsuo, Masashi Kurimoto, Hiroshi Yamauchi
-
Patent number: 7731941Abstract: A staining composition for staining an ophthalmic membrane when performing the ophthalmic membrane removal, wherein the staining composition comprises a Brilliant Blue G (BBG) derivative as a primary component.Type: GrantFiled: December 6, 2005Date of Patent: June 8, 2010Assignee: National University Corporation Kyushu UniversityInventors: Hiroshi Enaida, Toshio Hisatomi, Tatsuro Ishibashi, Tadahisa Kagimoto, Yasuaki Hata
-
Patent number: 7728043Abstract: The invention provides methods for treating beta-amyloid protein-involved ocular disease including age-related macular degeneration and glaucoma, pharmaceutical compositions and compounds useful for the same, and the use of these compounds for the manufacture of a medicament for treating the same. More particularly, the invention relates to the use of natural product compounds isolated from Curcuma sp., Zingiber sp., Ginkgo biloba, Salvia sp., and Rosmarinus sp. and synthetic chemical analogues thereof, for the treatment of a beta-amyloid protein-involved ocular disease.Type: GrantFiled: November 23, 2005Date of Patent: June 1, 2010Inventor: Darrick S. H. L. Kim
-
Patent number: 7723287Abstract: A pharmaceutical composition for the treatment of disorders of the anterior segment of the eye or for the preservation of isolated cornea. The composition comprises, as an active ingredient, an agent capable of causing a net efflux of cholesterol from cells.Type: GrantFiled: January 13, 1998Date of Patent: May 25, 2010Assignee: Ramot At Tel-Aviv University Ltd.Inventors: Naphtali Savion, Arieh Solomon
-
Patent number: 7662855Abstract: Compositions for topical application for treating a skin disorder (e.g., acne) include a retinoid, which is solubilized completely in alcohol only with the aid of cosolvents such as esters (e.g., alkyl benzoate, isopropyl palmitate, isopropyl myristate, diisopropyl adipate and their derivatives). This completely solubilized retinoid can be used to formulate an emulsion system or liquid to powder suspension containing a second active, such as an antibiotic (e.g., clindamycin).Type: GrantFiled: November 9, 2004Date of Patent: February 16, 2010Assignee: Imaginative Research Associates, Inc.Inventors: Mohan Vishnupad, Naomi Vishnupad
-
Patent number: RE42243Abstract: A viscoelastic composition for injection into a human eye comprised of about 2.0 to 2.5 percent of hydroxypropyl methylcellulose dissolved in a physiological salt solution, the composition, the composition having a viscosity from about 15,000 to about 40,000 centipoise and the hydroxypropyl methylcellulose having a molecular weight from about 220,000 to less than about 420,000 Daltons, the composition being free of debris or gels greater than 0.5 ?m. Also described is a process for preparing the clean, high molecular weight hydroxy propylmethyl cellulose composition.Type: GrantFiled: June 5, 1997Date of Patent: March 22, 2011Assignee: Alcon, Inc.Inventor: Bradford C. Webb